Thomas Adrian

Prof. Thomas Adrian


Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2006 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
MUMichael B Ujiki
Michael B Ujiki
XDXian-Zhong Ding
Xian-Zhong Ding
MSM Reza Salabat
M Reza Salabat
DBDavid J Bentrem
David J Bentrem
LGLaleh Golkar
Laleh Golkar
TAThomas Adrian
Thomas Adrian
Background: Many chemotherapeutic agents have been used to treat pancreatic cancer without success. Apigenin, a naturally occurring flavonoid, has been shown to inhibit growth in some cancer cell lines but has not been studied in pancreatic cancer. We hypothesized that apigenin would inhibit pancreatic cancer cell growth in vitro. Results: Apigenin caused both time- and concentration-dependent inhibition of DNA synthesis and cell proliferation in four pancreatic cancer cell lines. Apigenin induced G2/M phase cell cycle arrest. Apigenin reduced levels of cyclin A, cyclin B, phosphorylated forms of cdc2 and cdc25, which are all proteins required for G2/M transition. Conclusion: Apigenin inhibits growth of pancreatic cancer cells through suppression of cyclin B-associated cdc2 activity and G2/M arrest, and may be a valuable drug for the treatment or prevention of pancreatic cancer.

14 June 2012 in Diabetologia
Verified
Journal Article
Closed access
PDF file
TAThomas Adrian
Thomas Adrian
SGS. Gariballa
S. Gariballa
KPK. A. Parekh
K. A. Parekh
STS. A. Thomas
S. A. Thomas
HSH. Saadi
H. Saadi
AYA. A. Young
A. A. Young

29 September 2008 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
XLX. Li
X. Li
ARA. B. Roginsky
A. B. Roginsky
XDX.‐Z. Ding
X.‐Z. Ding
CWC. Woodward
C. Woodward
PCP. Collin
P. Collin
TAThomas Adrian
Thomas Adrian

1 November 2007 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
TAThomas Adrian
Thomas Adrian
There is an immense diversity of marine plants and animals from which an estimated 14,000 pharmacologically active compounds have been isolated. However, in terms of clinically useful anti-cancer agents, the oceans remain as a largely untapped resource. Indeed, there are currently only two compounds used in the clinic that are derived from marine sources. These are cytarabine, which is a deoxycitidine analogue and aplidine, which has both growth inhibitory and anti-angiogenic effects. This situation is likely to change rather dramatically in the near future, as attention has focused on the vast diversity of available agents from marine organisms. The increased pace of activity in this area has resulted in a several clinical trials of promising compounds with the probability that these will be followed by other drugs currently under preclinical development.

1 May 2014 in European Journal of Cancer
Verified
Journal Article
Closed access
JSJ. Al Shemaili
J. Al Shemaili
EME. Mensah-Brown
E. Mensah-Brown
KPK. Parekh
K. Parekh
STS.A. Thomas
S.A. Thomas
SAS. Attoub
S. Attoub
TAThomas Adrian
Thomas Adrian

19 February 2018 in Marine Drugs
Verified
Journal Article
Open access
PDF file
TAThomas Adrian
Thomas Adrian
PCPeter Collin
Peter Collin
Frondoside A is a triterpenoid glycoside from the Atlantic Sea Cucumber, Cucumaria frondosa. Frondoside A has a broad spectrum of anti-cancer effects, including induction of cellular apoptosis, inhibition of cancer cell growth, migration, invasion, formation of metastases, and angiogenesis. In cell lines and animal models studied to date, the anti-cancer effects of the compound are seen in all solid cancers, lymphomas, and leukemias studied to date. These effects appear to be due to potent inhibition of p21-activated kinase 1 (PAK1), which is up-regulated in many cancers. In mouse models, frondoside A has synergistic effects with conventional chemotherapeutic agents, such as gemcitabine, paclitaxel, and cisplatin. Frondoside A administration is well-tolerated. No side effects have been reported and the compound has no significant effects on body weight, blood cells, or on hepatic and renal function tests after long-term administration. Frondoside A may be valuable in the treatment of malignancies, either as a single agent or in combination with other therapeutic modalities.